Although effective and feasible means of reducing in-utero and intra-partum HIV transmission are now becoming available in resource-limited settings, prevention of post-partum transmission through breastfeeding remains a critical challenge. This study, now being conducted in collaboration with studies underway in Kampala, Uganda and Pune, India will evaluate the efficacy of a 6 week prophylactic regimen of nevirapine in the prevention of HIV transmission among breastfed infants. The primary endpoint is infant HIV infection status at 6 months of age. To date, 559 HIV seropositive women have been enrolled in this randomized, double-masked study with a 93% infant follow-up rate at 6 months of age. A total of 770 seropositive, breastfeeding women will be enrolled in Ethiopia. Enrollment will be completed in approximately 6-8 months with final follow-up of the women and their infants ending 12 months later. Breastfeeding among HIV-infected women continues to be supported in many resource poor settings because of the excess risk of morbidity and mortality associated with alternative feeding. However, at least one study has suggested that alternative feeding of infants born to HIV-infected women may not necessarily be associated with such increased risks. The study in Ethiopia is evaluating the risks associated with infant feeding practices by also enrolling and following two additional cohorts: non-breastfeeding HIV-infected woman and their infants and HIV negative women and their infants. Data from the randomized cohort study will assist in determining whether infant prophylaxis early in breastfeeding can significantly reduce post-partum transmission. As indicated above, feasible effective intervention strategies to prevent HIV transmission through breastfeeding are urgently needed. The data regarding morbidity and mortality rates by feeding modality will inform future policy decisions addressing the risks and benefits of a given feeding practice for HIV-infected women. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
2U01AI038576-06
Application #
6947617
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Sharma, Usha K
Project Start
1995-09-15
Project End
2007-02-28
Budget Start
2005-09-15
Budget End
2006-02-28
Support Year
6
Fiscal Year
2005
Total Cost
$271,035
Indirect Cost
Name
Johns Hopkins University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Onyango-Makumbi, Carolyne; Omer, Saad B; Mubiru, Michael et al. (2011) Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda (HIVIGLOB/NVP STUDY). J Acquir Immune Defic Syndr 58:399-407
Onyango-Makumbi, Carolyne; Bagenda, Danstan; Mwatha, Antony et al. (2010) Early weaning of HIV-exposed uninfected infants and risk of serious gastroenteritis: Findings from two perinatal HIV prevention trials in Kampala, Uganda. J Acquir Immune Defic Syndr 53:20-7
Church, Jessica D; Huang, Wei; Mwatha, Anthony et al. (2010) Analysis of HIV tropism in Ugandan infants. Curr HIV Res 8:498-503
Church, Jessica D; Mwatha, Anthony; Bagenda, Danstan et al. (2009) In utero HIV infection is associated with an increased risk of nevirapine resistance in ugandan infants who were exposed to perinatal single dose nevirapine. AIDS Res Hum Retroviruses 25:673-7
Church, Jessica D; Huang, Wei; Parkin, Neil et al. (2009) Comparison of laboratory methods for analysis of non-nucleoside reverse transcriptase inhibitor resistance in Ugandan infants. AIDS Res Hum Retroviruses 25:657-63
Church, Jessica D; Omer, Saad B; Guay, Laura A et al. (2008) Analysis of nevirapine (NVP) resistance in Ugandan infants who were HIV infected despite receiving single-Dose (SD) NVP versus SD NVP plus daily NVP up to 6 weeks of age to prevent HIV vertical transmission. J Infect Dis 198:1075-82